Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GSK taps Entelos to conduct in silico research
March 2009
SHARING OPTIONS:

LONDON—GlaxoSmithKline plc last month announced it signed an agreement with predictive disease simultation provider Entelos Inc. to conduct in silico research using the Entelos Hematopoeisis PhysioLab platform. The collaboration is the third in a series of projects Entelos has conducted across multiple therapeutic areas at GSK for several years. The Hematopoeisis PhysioLab platform is a computer model that can simulate the complex biology of anemic patients and large "virtual patient populations" to predict responses to drugs. It has been used with other pharmaceutical partners to assess the safety and efficacy of biologics, find the best doses for specific patient types and optimize complicated, adaptive clinical trial designs to better position products in the highly competitive market for anti-anemia drugs.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.